Stockscreener 앱 받기
11.82
1.75%
-0.21
시간 외 거래:
11.56
-0.26
-2.20%
전일 마감가:
$12.03
열려 있는:
$12.47
하루 거래량:
322.03K
Relative Volume:
0.78
시가총액:
$320.56M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-10.19
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
-2.72%
1개월 성능:
-7.80%
6개월 성능:
-32.50%
1년 성능:
-69.23%
1일 변동 폭
$11.70
$12.50
1주일 범위
$11.70
$13.00
52주 변동 폭
$8.04
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
11.82 | 329.52M | 157.75M | -29.73M | -21.00M | -1.16 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
When the Price of (ARCT) Talks, People Listen - news.stocktradersdaily.com
Scotiabank Initiates Coverage on Arcturus Therapeutics (ARCT) | - GuruFocus
Arcturus Therapeutics (ARCT) Receives Positive Outlook with Potential Upside | ARCT Stock News - GuruFocus
Scotiabank Initiates Arcturus Therapeutics at Outperform - marketscreener.com
Man Group plc Sells 4,168 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics’ SWOT analysis: mRNA innovator’s stock faces pivotal year - Investing.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A 481% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Northern Trust Corp Has $4.35 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $45.00 - Defense World
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics - MSN
FY2025 EPS Estimates for ARCT Raised by Cantor Fitzgerald - The AM Reporter
Leerink Partnrs Analysts Raise Earnings Estimates for ARCT - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
William Blair Brokers Boost Earnings Estimates for ARCT - Defense World
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - Defense World
Arcturus Therapeutics (ARCT): Wells Fargo Maintains Rating, Lowe - GuruFocus
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT - GuruFocus
Arcturus Therapeutics (ARCT) Set for Potential Upside with Citi's Confidence | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $4.11, revenue fell short of estimates - Investing.com Nigeria
Canaccord Genuity Maintains Buy Rating on Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews - Benzinga
Arcturus Therapeutics (ARCT) Price Target Revised by Canaccord | - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... - Yahoo Finance
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Reports Q1 2025 Financial Update - TipRanks
Arcturus Therapeutics (ARCT) Sees Strong Progress with Pipeline Programs - GuruFocus
Earnings call transcript: Arcturus Therapeutics Q1 2025 sees revenue drop, stock rises - Investing.com
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcturus Therapeutics (ARCT) Surpasses Q1 Revenue Expectations | - GuruFocus
ARCTURUS THERAPEUTICS Earnings Results: $ARCT Reports Quarterly Earnings - Nasdaq
Arcturus Therapeutics stock jumps 7% despite Q1 loss By Investing.com - Investing.com Canada
Arcturus Therapeutics stock jumps 7% despite Q1 loss - Investing.com Australia
Arcturus Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress - Business Wire
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Dimensional Fund Advisors LP - Defense World
Arcturus Therapeutics (ARCT) to Release Quarterly Earnings on Monday - Defense World
Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result - Yahoo Finance
MetLife Investment Management LLC Has $283,000 Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Barclays PLC Sells 7,333 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Yahoo Finance
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.70%
1.64%
자본화:
|
볼륨(24시간):